|
WO2018221728A1
|
|
Agent for preventing or treating alzheimer-type dementia
|
|
CN110691595A
|
|
Agent for reducing amount of beta-amyloid
|
|
WO2018221731A1
|
|
Agent for preventing or treating tauopathy
|
|
WO2018143162A1
|
|
COMPOUND SERVING AS PRODRUG OF HYDROXAMIC ACID OR SALT OF SAID COMPOUND, FREEZE-DRIED MEDICINAL PREPARATION, LpxC INHIBITOR, AND ANTIBACTERIAL
|
|
WO2018124281A1
|
|
Topical composition
|
|
WO2018124284A1
|
|
Pharmaceutical composition
|
|
TW201808291A
|
|
Method of producing lyophilized preparation
|
|
WO2017188361A1
|
|
Tablet containing tosufloxacin tosilate
|
|
TW201740942A
|
|
Tablet comprising tosufloxacin tosilate, disintegrant and acidic amino acid
|
|
CN109311806A
|
|
The manufacturing method and its intermediate of new hydroxamic acid derivs
|
|
WO2017126648A1
|
|
Pharmaceutical composition containing n-[7-[(methylsulfonyl)amino]-4-oxo-6-phenoxy-4h-1-benzopyran-3-yl]formamide or salt thereof
|
|
WO2017111005A1
|
|
Tablet comprising 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or salt thereof
|
|
CN108135891A
|
|
anti-hepatitis B virus medicine
|
|
WO2017061431A1
|
|
Tablet containing solithromycin
|
|
WO2017038815A1
|
|
Crystals of 5-cyclopropyl-2-((1-(3-fluorobenzyl)-1h-indol-5-yl)amino)nicotinic acid
|
|
JP2017200839A
|
|
Container for conveyance
|
|
JP2017014199A
|
|
Manufacturing method of novel hydroxamic acid derivative
|
|
EP3308782A1
|
|
Sigma-receptor binding agent
|
|
WO2016039433A1
|
|
Novel pharmaceutical composition containing hydroxamic acid derivative or salt thereof
|
|
WO2016039432A1
|
|
Method for using novel hydroxamic acid derivative and antibacterial substance in combination
|
